Immunovant

NEW YORK, NY · CIK 0001764013 · Biotech · Public

Batoclimab, an FcRn inhibitor monoclonal antibody that reduces pathogenic IgG antibodies

immunovant.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$450M
1 Form D · Jan 2025
20 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$450,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2164Arctus Biosciences——
2165NEMALIFE INC——
2166PRIME LABS INC——
2167Immunovant—$450M
2168Ocugen—$126M
2169VISIONARY PHARMACEUTICALS, INC.——
2170Excision BioTherapeutics Inc.—$71M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 13 related persons
  • Eva Renee BarnettExecutive Officer
  • Andrew FromkinDirector
  • Michael GeffnerExecutive Officer
  • Melanie GloriaExecutive Officer
  • Douglas HughesDirector
  • Bill MaciasExecutive Officer
  • George MigauskyDirector
  • Atul PandeDirector
  • Pete SalzmannDirector · Executive Officer
  • Jay StoutExecutive Officer
  • Frank TortiDirector
  • Christopher Van TuylExecutive Officer
  • Eric VenkerDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.